Pfizer Execs Seek Dismissal Of Derivative Suit
On the heels of Pfizer Inc. agreeing to pay the U.S. government $2.3 billion to settle allegations of off-label drug promotion, top brass at the company are seeking to dismiss related...To view the full article, register now.
Already a subscriber? Click here to view full article